 |
|
|
| |
GS-6620, A Liver-Targeted Nucleotide Prodrug, Exhibits Antiviral Activity and Favorable Safety Profile Over 5 Days in Treatment Naïve Chronic HCV Genotype 1 Subjects
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
E. Lawitz1, J. Hill2, T. Marbury3, L. Hazan4, D. Gruener5, L. Webster6, R. Majauskas7, R. Morrison8, M. DeMicco9, P. German10, D. Stefanidis10, E. Svaroskaia10, S. Arterburn10, A. Ray10, S. Rossi10, J. McHutchison10, M. Rodriguez-Torres11
1Alamo Medical Research, San Antonio, TX, 2Avail Clinical Research, Deland, FL, 3Orlando Clinical Research Center, Orlando, FL, 4Axis Clinical Trials, Los Angeles, CA, 5CRI Worldwide, Philadelphia, PA, 6Lifetree Clinical Research, Salt Lake City, UT, 7University of Florida, Gainesville, FL, 8Comprehensive Clinical Development, Tacoma, WA, 9Advanced Clinical Research, Anaheim, CA, 10Gilead Sciences, Foster City, CA, 11Fundacion de Investigacion de Diego, San Juan, PR
|
| |
|
|
|
|
|
